Bill is the Co-chair of the Life Sciences Practice Group and a member of the firm's Policy Committee. He has extensive experience representing issuers, investors, and investment banks in structuring and executing IPOs, cross-over investments, alternative public offerings, including APOs, reverse mergers and Form 10 transactions, follow-on public offerings, CMPOs, registered directs, PIPEs, and private placements.
Bill represents hedge funds, venture capital firms, and private equity firms in customized investments in public companies, including structured PIPEs and registered directs. Bill also represents public companies in public and private financings, SEC compliance, corporate governance, and general counseling.
Bill has extensive experience representing buyers and sellers in M&A transactions, including public company deals, private company deals, and spin-offs. Bill regularly represents domestic and foreign companies and is well versed in issues specific to cross-border deals.
Additionally, Bill represents private companies and investors in venture capital transactions.
viewpoints
Frequently Asked Questions for Private Companies Considering a Reverse Merger
February 13, 2024 | Article | By William Hicks, John T. Rudy
Reverse mergers aren’t an alternative to an IPO, rather they can be a strategic approach for companies looking to go public by leveraging “fallen angels”. Mintz Members Bill Hicks and John Rudy answer frequently asked questions for private companies considering a reverse merger in an article featured in PitchBook’s 2023 Annual US VC Valuations Report. The authors detail the benefits and challenges associated with a reverse merger including finding partners, PIPE financing, Nasdaq access for non-US companies, and SEC implications.
News & Press
Mintz Advises on Verastem Oncology’s $250 Million Underwritten Offering
October 15, 2026|
Mintz Advises on Atrium Therapeutics’ $50 Million Private Placement
October 12, 2026|
Mintz Advises on Edesa Biotech’s $25 Million Public Offering
August 25, 2026|
Mintz Advises on $200 Million Private Placement Concurrent with Vidya Therapeutics’ and Processa Pharmaceuticals’ Merger Transaction
August 04, 2026
Mintz advised the placement agents on the $200 Million private placement in connection with Processa Pharmaceuticals, Inc.’s acquisition of Vidya Therapeutics, Inc.
Mintz advised the placement agents in connection with LB Pharmaceuticals’ $150 Million private placement of common stock and pre-funded warrants.
Mintz Advises on uniQure’s $259 Million Public Offering
June 25, 2026|
Mintz Advises on ImageneBio’s $30 Million Private Placement
April 15, 2026|
Mintz Advises on Wave Life Sciences $402.5 Million Public Offering
December 12, 2025|
Mintz Advises on Capricor Therapeutics’ $150 Million Public Offering
December 10, 2025|
Mintz Advises on Verastem Oncology’s $103 Million Public Offering
November 21, 2025|
Mintz Advises on Eledon Pharmaceuticals’ $50 Million Follow-on Offering
November 20, 2025|
Mintz Advises on MoonLake Immunotherapeutics’ $75 Million Offering
November 12, 2025|
Mintz Advises on uniQure's $345 Million Public Offering
September 30, 2025|
Mintz Advises on LB Pharmaceuticals’ $285 Million Initial Public Offering
September 12, 2025|
Mintz Advises on Equillium, Inc.'s up to $50 Million PIPE
August 15, 2025|
Mintz Advises on $90 Million Underwritten Offering by Rezolute
April 25, 2025|
The Business of Biotech
November 29, 2024|
Thomson Reuters Recognizes 10 Mintz Attorneys as “Stand-out Lawyers”
February 20, 2024|
Deal Watch: Where Did All the IPOs Go?
September 26, 2022|
Spotlight on SPACs: The Dog Days of Summer
August 10, 2022|
podcasts
Between the Biotech Waves Conversation with William Hicks
April 16, 2025 | Podcast
The Life Sci Fantastic Podcast - The Business of Biotech
November 28, 2024 | Podcast
A Between The Biotech Waves Conversation With William Hicks
June 10, 2022 | Podcast
Bill Hicks was a guest on Between the Biotech Waves with Nessan Bermingham.
Events & Speaking
Attracting International Investment to Nordic Life Sciences and Examining Late-Stage Opportunities
LSX Nordic Congress
Copenhagen, Denmark
Inside the Life Sciences Industry Public Company Playbook: Strategies, Risks & Realities
Inside From IPO ambitions to public company survival—join leading life sciences industry voices for insights into the forces shaping today’s market.
Mintz San Diego Office
Creative Disruption Forum & Agile Leaders Forum on Investment and Dealmaking Strategies
Keynote Interviews
London, UK
Navigating the Path to IPO: Preparing Your Biotech Company for the Public Markets
Investival Showcase USA
Miami, FL
Navigating Biotech Funding Dynamics: Is Flat the New Up? Shifts in Public and Private Finance
LSX Inv€$tival Showcase™
London, UK
The Next Phase In US Healthcare Investment – What Have We Seen, And Where Are We Going?
LSX Investival Showcase
Virtual Event
Sustainable Ecosystem for Bio/MedTech Startups
12th New York Health Forum
Yale Club Manhattan, Trumbull & Saybrook Room, 18th Floor
Boston Biotech CEO Conference
Boston Biotech Conferences
Four Seasons Hotel, 200 Boylston Street, Boston, MA
Recognition & Awards
Ranked in Chambers Massachusetts: Capital Markets (2026)
Shortlisted as LMG Life Sciences Venture Capital Attorney of the Year – US (2025)
Legal 500 United States: Recognized for Healthcare: Life Sciences (2020, 2025); Capital Markets: Equity (2021 – 2022, 2024)
Ranked by Lexology Index for Healthcare & Life Sciences – Transactional (2025)
Who’s Who Legal: Global Leader – Life Sciences (2023)
Thomson Reuters: Stand-out Lawyers (2024)
Who’s Who Legal: Life Sciences – Transactional (2019)
LMG Life Sciences: Financial & Corporate, Corporate, Mergers & Acquisitions, Venture Capital US Life Sciences Star (2018 – 2019)
Recent Insights
Mintz Advises on Verastem Oncology’s $250 Million Underwritten Offering
October 15, 2026|
Mintz Advises on Atrium Therapeutics’ $50 Million Private Placement
October 12, 2026|
